New Results from EMPHASIS-HF Show Big Benefits For High Risk Subgroups Taking Eplerenone - Forbes
Links shared publicly online about this topic.
- 37total visits
New Results from EMPHASIS-HF Show Big Benefits For High Risk Subgroups Taking Eplerenone - Forbes
Last November the main results of the EMPHASIS-HF trial demonstrated that eplerenone was significantly better than placebo in reducing the risk of death and hospitalization in patients with systolic heart failure and mild symptoms. Now a new analysis of the trial, presented by Bertram Pitt at the European Society of [...]
View full resource at forbes.com
Tags: Heart, Heart Disease, Heart Failure, Drug, Mortality
Most Recently Shared on August 29, 2011 at 6:16 pm By:
New Results from EMPHASIS-HF Show Big Benefits For High Risk Subgroups Taking Eplerenone: Last November... http://t.co/M5fy6Ho #drug
Advertisement
